Risk stratification of oesophageal squamous cell carcinoma using change in total lesion glycolysis and number of PET-positive lymph nodes

Br J Cancer. 2023 May;128(10):1879-1887. doi: 10.1038/s41416-023-02151-y. Epub 2023 Feb 25.

Abstract

Background: The efficacy of neoadjuvant chemotherapy (NACT) correlates with patient survival in oesophageal squamous cell carcinoma (OSCC), but optimal evaluation of the treatment response based on PET-CT parameters has not been established.

Methods: We analysed 226 OSCC patients who underwent PET-CT before and after NACT followed by surgery. We assessed SUVmax, metabolic tumour volume (MTV), and total lesion glycolysis (TLG) for the primary tumour and the number of PET-positive lymph nodes before and after NACT to predict patient survival.

Results: In a stepwise analysis, we defined 60%, 80%, and 80% as the optimal cut-off values for SUVmax, MTV, and TLG reduction, respectively, to distinguish responders and non-responders to NACT. In the ROC analysis, the TLG reduction rate was the best predictor of recurrence among PET-CT parameters. The TLG responders achieved significantly more favourable prognoses than non-responders (2-year progression-free survival [PFS] rate: 64.1% vs. 38.5%; P = 0.0001). TLG reduction rate (HR 2.58; 95% CI 1.16-5.73) and the number of PET-positive lymph nodes after NACT (HR 1.79; 95% CI 1.04-3.08) were significant independent prognostic factors.

Conclusions: TLG reduction is the best predictor of prognosis. Preoperative PET-CT evaluation of both the primary tumour and lymph nodes could accurately stratify risk in OSCC patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Esophageal Neoplasms* / diagnostic imaging
  • Esophageal Neoplasms* / metabolism
  • Esophageal Neoplasms* / therapy
  • Esophageal Squamous Cell Carcinoma* / diagnostic imaging
  • Esophageal Squamous Cell Carcinoma* / metabolism
  • Fluorodeoxyglucose F18
  • Glycolysis
  • Humans
  • Lymph Nodes / diagnostic imaging
  • Lymph Nodes / metabolism
  • Positron Emission Tomography Computed Tomography
  • Prognosis
  • Radiopharmaceuticals / metabolism
  • Retrospective Studies
  • Risk Assessment
  • Tumor Burden

Substances

  • Fluorodeoxyglucose F18
  • Radiopharmaceuticals